Gefitinib (Iressa) in oncogene-addictive cancers and therapy for common cancers

Cancer Biology and Therapy

Volumn 3, Issue 5, 2004, Pages 436-440

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Bcr Abl; Cancer; Chemotherapy; EGF; Gefitinib; Imatinib; Iressa; Oncogene

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CASPASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVOPIRIDOL; GEFITINIB; GELDANAMYCIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; PHORBOL ESTER DERIVATIVE; RAPAMYCIN; RETINOIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; QUINAZOLINE DERIVATIVE;

ACNE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE; RASH; DRUG ANTAGONISM; DRUG EFFECT; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; GENES, ABL; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 10944269712     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.5.984     Document Type: Article

References (66)

1. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WDJ, Morse D, et al. United states food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10:1212-8.
2. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20:1S-13S.
3. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
4. Wilkinson E. Surprise phase III failure for ZD1839. Lancet Oncol 2002; 3:583.
5. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-94.
6. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-302.
7. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-24.
8. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003; 17:23-8.
9. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 2002; 7:31-9.
10. Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed: Toward novel use of kinase inhibitors (Outlook). Cancer Biol Ther 2003; 2:137-40.
11. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: Small molecules, big hopes. J Clin Oncol 2002; 20:2217-9.
12. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practice. Clin Cancer Res 2003; 9:1579-89.
13. Castro M. The simpleton's error in drug development. J Clin Oncol 2002; 20:4606-4607.
14. Giaccone G, Gonzalez-Larriba JL, Van Oosterom AT, Alfonso R, Smit EF, Martens M, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 2004; 15:831-8.
15. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in nonsmall-cell lung cancer: How do we go from INTACT to impact? J Clin Oncol 2004; 22:759-61.
16. Haringhuizen A, Van Tinteren H, Vaessen HF, Baas P, Van Zandwijk N. Gefitinib as a last treatment option for nonsmall-cell lung cancer: Durable disease control in a subset of patients. Ann Oncol 2004; 15:786-92.
17. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; In press.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; In press.
19. Normanno N, Di Maio M, Perrone F, Campiglio M. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or More? J Clin Oncol 2004; 22:2035-6.
20. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1:31-6.
21. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
22. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17:2998-3010.
23. Weinstein IB. Cancer addiction to oncogenes - the achilles heal of cancer. Science 2002; 29:63-4.
24. Giuriato S, Felsher DW. How cancers escape their oncogene habit. Cell Cycle 2003; 2:329-32.
25. Blagosklonny MV. Do cells need CDK2 and ... Bcr-Abl? Cell Death Differ 2004; 11:249-51.
26. 2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86:1148-58.
27. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998; 91:1700-5.
28. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998; 91:2415-22.
29. L. Oncogene 1998; 16:1383-90.
30. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000; 20:1179-86.
31. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18:189-218.
32. Zheng TS, Hunot S, Kuida K, Momoi T, Srinivasan A, Nicholson D, et al. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nat Med 2000; 6:1241-7.
33. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor. N Engl J Med 2002; 347:481-7.
34. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, et al. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol 2004; 122:400-5.
35. Sawyers CL. FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002; 1:413-5.
36. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2:296-313.
37. Arteaga CL. Inhibiting tyrosine kinases: Successes and limitations. Cancer Biol Ther 2003; 2:S79-83.
38. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300:949.
39. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9:138-41.
40. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nature Rev Cancer 2002; 2:221-5.
41. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812-22.
42. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
43. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7.
44. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001; 15:1537-43.
45. Cox AD, Der CJ. Ras family signaling: Therapeutic targeting. Cancer Biol Ther 2002; 1:599-606.
46. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22:7389-95.
47. Daley GQ. Gleevec resistance: Lessons for target-directed drug development. Cell Cycle 2003; 2:190-1.
48. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004; 206:149-57.
49. Workman P. Strategies for treating cancers caused by multiple genome abnormalities: From concepts to cures? Curr Opin Investig Drugs 2003; 4:1410-5.
50. Pack SD, Alper OM, Stromberg K, Augustus M, Ozdemirli M, Miermont AM, et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res 2004; 64:789-94.
51. Rahmani M, Grant S. UCN-01 (7-hydroxystaurosporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937). Cell Cycle 2002; 1:273-81.
52. Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21 (CIP1/WAF1) induction rather than AKT inhibition. Oncogene 2003; 18:6231-42.
53. Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, et al. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 2003; 2:670-6.
54. Grant S, Dent P. Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors. Cell Cycle 2002; 1:383-8.
55. Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, Grant S. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004; 103:2761-70.
56. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to Tumor Necrosis Factor. Cancer Res 2004; 64:3653-60.
57. Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV, et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 2002; 21:119-27.
58. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004; 3:51-60.
59. Kamasani U, Liu AX, Prendergast GC. Genetic response to farnesyltransferase inhibitors: Proapoptotic targets of RhoB. Cancer Biol Ther 2003; 2:273-80.
60. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: Protection of normal cells and unshielding of cancer cells. Cell Cycle 2002; 1:375-82.
61. Du L, Smolewski P, Bedner E, Traganos F, Darzynkiewicz Z. Selective protection of mitogenically stimulated human lymphocytes but not leukemic cells from cytosine arabinoside-induced apoptosis by LY294002, a phosphoinositol-3 kinase inhibitor. Int J Oncol 2001; 19:811-9.
62. 1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002; 1:82-89.
63. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today 2003; 8:1104-7.
64. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001; 15:936-94.
65. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003; 13:135-47.
66. L in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death Differ 2004; 11:583-7.